While the reduction in price target from $24 to $22 by RBC Capital might initially seem negative, the maintenance of an Outperform rating by analyst Gregory Renza suggests a continued positive outlook on Nurix Therapeutics. The adjustment in price target reflects a recalibration of expectations rather than a fundamental shift in the company's prospects. Investors might see this as a nuanced adjustment rather than a cause for concern.